Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet’s disease

IF 1.5 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

Clinical and Experimental Hypertension Pub Date : 2022-05-03 DOI:10.1080/10641963.2022.2071921

R. Aydogan Baykara, Pinar Diydem Yilmaz, M. H. Göktepe, C. Kadıyoran, Mustafa Ogul, A. Kucuk, Medine Cumhur Cüre, Erkan Cüre

{"title":"Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet’s disease","authors":"R. Aydogan Baykara, Pinar Diydem Yilmaz, M. H. Göktepe, C. Kadıyoran, Mustafa Ogul, A. Kucuk, Medine Cumhur Cüre, Erkan Cüre","doi":"10.1080/10641963.2022.2071921","DOIUrl":null,"url":null,"abstract":"ABSTRACT Objectives The incidence of cardiovascular disease is increased in patients with Behcet’s disease (BD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) causes the acceleration of atherosclerosis. We aimed to investigate whether there is a relationship between PCSK9 with carotid artery intima-media thickness (cIMT), a marker of subclinical atherosclerosis, and BD disease activity. Methods Fifty-eight patients with BD and 58 age-, gender-, and body mass index (BMI)-matched healthy control subjects were included in the study. The disease activity of the patients was estimated. Individuals’ cIMT values were measured, and PCSK9 levels were studied. Results Patients with BD’ cIMT (0.51 ± 0.1 vs 0.41 ± 0.1 mm, p < .001) and PCSK9 (623.2 ± 101.7 ± 10.1 vs 528.3 ± 242.7 ng/ml, p = .007), values were significantly higher than the control group. In stepwise regression analysis, there was an independent relationship between cIMT with PCSK9 (β = 0.179, p < .050). There was no independent relationship between disease activities with PCSK9. Based on the ROC curve analysis, the PCSK9 optimal cutoff value for cIMT was 595.1 ng/ml, sensitivity 66.7%, specificity 64.7% (AUC = 0.672; 95% CI: 0.530–0.815, p = .040). Conclusion There is a strong independent association between subclinical atherosclerosis and PCSK9 in patients with BD. There may be no independent association between PCSK9 and disease activity.","PeriodicalId":10333,"journal":{"name":"Clinical and Experimental Hypertension","volume":"10 1","pages":"480 - 486"},"PeriodicalIF":1.5000,"publicationDate":"2022-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10641963.2022.2071921","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 1

Abstract

ABSTRACT Objectives The incidence of cardiovascular disease is increased in patients with Behcet’s disease (BD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) causes the acceleration of atherosclerosis. We aimed to investigate whether there is a relationship between PCSK9 with carotid artery intima-media thickness (cIMT), a marker of subclinical atherosclerosis, and BD disease activity. Methods Fifty-eight patients with BD and 58 age-, gender-, and body mass index (BMI)-matched healthy control subjects were included in the study. The disease activity of the patients was estimated. Individuals’ cIMT values were measured, and PCSK9 levels were studied. Results Patients with BD’ cIMT (0.51 ± 0.1 vs 0.41 ± 0.1 mm, p < .001) and PCSK9 (623.2 ± 101.7 ± 10.1 vs 528.3 ± 242.7 ng/ml, p = .007), values were significantly higher than the control group. In stepwise regression analysis, there was an independent relationship between cIMT with PCSK9 (β = 0.179, p < .050). There was no independent relationship between disease activities with PCSK9. Based on the ROC curve analysis, the PCSK9 optimal cutoff value for cIMT was 595.1 ng/ml, sensitivity 66.7%, specificity 64.7% (AUC = 0.672; 95% CI: 0.530–0.815, p = .040). Conclusion There is a strong independent association between subclinical atherosclerosis and PCSK9 in patients with BD. There may be no independent association between PCSK9 and disease activity.

查看原文本刊更多论文

蛋白转化酶枯草杆菌素/ keexin 9型与白塞氏病患者动脉粥样硬化相关

【摘要】目的白塞氏病(BD)患者心血管疾病的发生率增高。蛋白转化酶枯草素/键合蛋白9型(PCSK9)导致动脉粥样硬化加速。我们的目的是研究PCSK9与颈动脉内膜-中膜厚度(cIMT)(亚临床动脉粥样硬化的标志)和BD疾病活动性之间是否存在关系。方法将58例BD患者和58例年龄、性别、体重指数(BMI)匹配的健康对照者纳入研究。估计患者的疾病活动性。测量个体的cIMT值，研究PCSK9水平。结果BD组患者cIMT(0.51±0.1 vs 0.41±0.1 mm, p < 0.001)、PCSK9(623.2±101.7±10.1 vs 528.3±242.7 ng/ml, p = 0.007)值均显著高于对照组。逐步回归分析显示，cIMT与PCSK9呈独立相关(β = 0.179, p < 0.050)。疾病活动与PCSK9之间没有独立的关系。ROC曲线分析显示，PCSK9检测cIMT的最佳临界值为595.1 ng/ml，灵敏度66.7%，特异性64.7% (AUC = 0.672;95% CI: 0.530-0.815, p = 0.040)。结论BD患者亚临床动脉粥样硬化与PCSK9有较强的独立相关性，PCSK9与疾病活动度可能无独立相关性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Hypertension 医学-外周血管病

CiteScore

3.90

自引率

0.80%

发文量

审稿时长

6-12 weeks

期刊介绍： Clinical and Experimental Hypertension is a reputable journal that has converted to a full Open Access format starting from Volume 45 in 2023. While previous volumes are still accessible through a Pay to Read model, the journal now provides free and open access to its content. It serves as an international platform for the exchange of up-to-date scientific and clinical information concerning both human and animal hypertension. The journal publishes a wide range of articles, including full research papers, solicited and unsolicited reviews, and commentaries. Through these publications, the journal aims to enhance current understanding and support the timely detection, management, control, and prevention of hypertension-related conditions. One notable aspect of Clinical and Experimental Hypertension is its coverage of special issues that focus on the proceedings of symposia dedicated to hypertension research. This feature allows researchers and clinicians to delve deeper into the latest advancements in this field. The journal is abstracted and indexed in several renowned databases, including Pharmacoeconomics and Outcomes News (Online), Reactions Weekly (Online), CABI, EBSCOhost, Elsevier BV, International Atomic Energy Agency, and the National Library of Medicine, among others. These affiliations ensure that the journal's content receives broad visibility and facilitates its discoverability by professionals and researchers in related disciplines.